Soluble Aβ Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway
Open accessThe DOI matches its Crossref record; 53 of the 55 references it cites were found in a registry or an index.
Abstract
Numerous studies have now shown that the amyloid beta-protein (Abeta), the principal component of cerebral plaques in Alzheimer disease, rapidly and potently inhibits certain forms of synaptic plasticity. The amyloid (or Abeta) hypothesis proposes that the continuous disruption of normal synaptic physiology by Abeta contributes to the development of Alzheimer disease. However, there is little consensus about how Abeta mediates this inhibition at the molecular level. Using mouse primary hippocampal neurons, we observed that a brief treatment with cell-derived, soluble, human Abeta disrupted the activation of three kinases (Erk/MAPK, CaMKII, and the phosphatidylinositol 3-kinase-activated protein Akt/protein kinase B) that are required for long term potentiation, whereas two other kinases (protein kinase A and protein kinase C) were stimulated normally. An antagonist of the insulin receptor family of tyrosine kinases was found to mimic the pattern of Abeta-mediated kinase inhibition. We then found that soluble Abeta binds to the insulin receptor and interferes with its insulin-induced autophosphorylation. Taken together, these data demonstrate that physiologically relevant levels of naturally secreted Abeta interfere with insulin receptor function in hippocampal neurons and prevent the rapid activation of specific kinases required for long term potentiation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“If Akt is not phosphorylated, GSK3-β remains active [93] and is described as responsible for events related to AD pathology, including the hyperphosphorylation of Tau [94].”
From Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease (2014) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Self-citationDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Mechanism of activation of protein kinase B by insulin and IGF-1.
Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., & Hemmings, B. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01045.x · Cited by 3,004
Long-Term Potentiation and Memory
LYNCH, M. A. (2004) · Physiological Reviews · doi:10.1152/physrev.00014.2003 · Cited by 1,991
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2005) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,687
Self-citationShankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Self-citationRegulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561
Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene
Montminy, M. R., & Bilezikjian, L. M. (1987) · Nature · doi:10.1038/328175a0 · Cited by 1,357
Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061
Cited by
Items 101–200 of 321
The role of PI3K signaling pathway in Alzheimer’s disease
Pan, J., Yao, Q., Wang, Y., Chang, S., Li, C., Wu, Y., Shen, J., & Yang, R. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1459025 · Cited by 89
“On the flip side, A β aggregation can induce GSK3 β activity through A β -mediated neuroinflammation and oxidative stress; it can also increase GSK3 β activity by preventing PI3K activation and subsequently preventing Akt activation (Townsend et al., 2007).”
BackgroundThe role of glycogen synthase kinase 3 in the early stages of Alzheimers’ disease
Hernández, F., & Avila, J. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.10.026 · Cited by 85
Adzovic, L., Lynn, A. E., D’Angelo, H. M., Crockett, A. M., Kaercher, R. M., Royer, S. E., Hopp, S. C., & Wenk, G. L. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0282-z · Cited by 94
“Aging is a risk factor for insulin resistance [55], and insulin signaling decrease is believed to be the cause that triggers the neurodegenerative processes [56], particularly in AD.”
BackgroundPitt, J., Wilcox, K. C., Tortelli, V., Diniz, L. P., Oliveira, M. S., Dobbins, C., Yu, X.-W., Nandamuri, S., Gomes, F. C. A., DiNunno, N., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-06-0416 · Cited by 84
“These findings confirm and extend previous indications that insulin signaling protects neurons against AβOs and AD pathogenesis (Townsend et al., 2007; Jolivalt et al., 2008; De Felice et al., 2009; Zhao et al., 2009; Craft et al., 2012; Long-Smith et al., 2013).”
ResultObesity, Insulin Resistance, and Alzheimer's Disease
Hildreth, K. L., Van Pelt, R. E., & Schwartz, R. S. (2012) · Obesity · doi:10.1038/oby.2012.19 · Cited by 86
Amyloid-β Induces Hepatic Insulin Resistance In Vivo via JAK2
Zhang, Y., Zhou, B., Deng, B., Zhang, F., Wu, J., Wang, Y., Le, Y., & Zhai, Q. (2013) · Diabetes · doi:10.2337/db12-0670 · Cited by 81
Pathogenesis of Abeta Oligomers in Synaptic Failure
Sivanesan, S., Tan, A., & Rajadas, J. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310030011 · Cited by 86
“The loss of surface insulin receptors (IRs) at the synapse by A oligomers or ADDLs [39] involves altered IR tyrosine autophosphorylation [37] and a mechanism sensitive to calcium calmodulin-dependent kinase II (CaMKII) and casein kinase II (CK2) inhibition [117] apart from the loss of activation of specific kinases re…”
BackgroundSirerol‐Piquer, M., Gomez‐Ramos, P., Hernández, F., Perez, M., Morán, M. A., Fuster‐Matanzo, A., Lucas, J. J., Avila, J., & García‐Verdugo, J. M. (2011) · Hippocampus · doi:10.1002/hipo.20805 · Cited by 81
“the APP, PS-1, and PS-2 proteins promote the onset of the disease (Price and Sisodia, 1998), which is associated with an increase in GSK3b activity (Baki et al., 2004; Avila, 2006; Kimura et al., 2007; Townsend et al., 2007).”
BackgroundSteculorum, S. M., Solas, M., & Brüning, J. C. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.008 · Cited by 92
“Soluble Ab reduces insulin’s ability to induce the PI3K/AKT pathway in cultured hippocampal neurons [52], whereas oligomers have been proposed to be responsible for the reduction in plasma membrane IRs in primary hippocampal neurons, promoting synaptic spine loss [51].”
Reifert, J., Hartung-Cranston, D., & Feinstein, S. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.234674 · Cited by 80
Moreira, P. I. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-111127 · Cited by 82
“Townsend and coworkers [135] reported that soluble A interfered with IR function where soluble peptide oligomers caused a loss of dendritic IRs and increased IR expression in the cell soma, but without changes in absolute hippocampal neuronal IR levels [136].”
Insulin resistance in the brain: An old-age or new-age problem?
Williamson, R., McNeilly, A. D., & Sutherland, C. D. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.05.007 · Cited by 96
“Soluble Abeta reduces insulin’s ability to induce the PI3K–PKB pathway in cultured hippocampal neurons [71], while soluble Ab oligomers reduce plasma membrane IR in primary hippocampal neurons, promoting synaptic spine loss [72].”
BackgroundThe role of GSK3 in Alzheimer disease
Hernández, F., de Barreda, E. G., Fuster-Matanzo, A., Goñi‐Oliver, P., Lucas, J. J., & Ávila, J. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.05.017 · Cited by 90
Zimbone, S., Monaco, I., Gianì, F., Pandini, G., Copani, A. G., Giuffrida, M. L., & Rizzarelli, E. (2018) · Aging Cell · doi:10.1111/acel.12684 · Cited by 79
“To this regard, A b oligomers have been shown to bind the insulin receptor (Xie et al. , 2002; Townsend et al. , 2007) and to promote a state of insulin resistance through the ERK-dependent phosphorylation of insulin receptor substrate-1 (Zhang et al. , 2015).”
Majd, S., Power, J. H. T., & Grantham, H. J. M. (2015) · BMC Neuroscience · doi:10.1186/s12868-015-0211-1 · Cited by 89
“Because these pathways eventually deactivate GSK3, their inhibition will result in hyperactivity of GSK3 [70, 71] (Fig.”
BackgroundDi, X., Yan, J., Zhao, Y., Zhang, J., Shi, Z., Chang, Y. Z., & Zhao, B. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.04.019 · Cited by 81
CaMKII Metaplasticity Drives Aβ Oligomer-Mediated Synaptotoxicity
Opazo, P., Viana da Silva, S., Carta, M., Breillat, C., Coultrap, S. J., Grillo-Bosch, D., Sainlos, M., Coussen, F., Bayer, K. U., Mulle, C., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.036 · Cited by 76
“Although our findings are consistent with the well-documented coupling between GluN2B and CaMKII, they are at odds with previous studies suggesting that oAβ inhibits rather than activates CaMKII (Gu et al., 2009; Townsend et al., 2007; Zhao et al., 2004).”
ResultAmyloid-β and Tau Pathology of Alzheimer's Disease Induced by Diabetes in a Rabbit Animal Model
Bitel, C. L., Kasinathan, C., Kaswala, R. H., Klein, W. L., & Frederikse, P. H. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120571 · Cited by 78
Clark, I. A., Atwood, C., Bowen, R. L., Paz-Filho, G., & Vissel, B. (2012) · Pharmacological Reviews · doi:10.1124/pr.112.005850 · Cited by 80
“Nevertheless, the implications of this link have not yet reached the AD literature, even though it dwells considerably on both inflammation and insulin resistance, two of the most recognized processes associated with the disease.”
BackgroundAlzheimer’s disease and type 2 diabetes via chronic inflammatory mechanisms
Mushtaq, G., Khan, J. A., Kumosani, T. A., & Kamal, M. A. (2015) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2014.05.003 · Cited by 71
“By interfering with insulin receptor function in the neurons, Ab prevents the rapid activation of certain kinases which are essential for long term potentiation (Xie et al., 2002; Townsend et al., 2007).”
BackgroundSignaling effect of amyloid-β42 on the processing of AβPP
Tabaton, M., Zhu, X., Perry, G., Smith, M. A., & Giliberto, L. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.002 · Cited by 66
“The MAPK pathway is often involved in Aβ-driven signaling, as downstream of Aβ-RAGE interaction (Yan et al., 2009), TrkA/p75NTR, insulin receptor (Townsend et al., 2007), and many more: in general, the MAPK signaling seems activated in AD (Lagalwar et al., 2006, Lee and Das, 2008, Zhu et al., 2002)…”
BackgroundLourenco, M. V., Ferreira, S. T., & Felice, F. G. D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.03.003 · Cited by 85
Park, S. A. (2011) · Journal of Clinical Neurology · doi:10.3988/jcn.2011.7.1.10 · Cited by 74
MAPK, β-amyloid and synaptic dysfunction: the role of RAGE
Origlia, N., Arancio, O., Domenici, L., & Yan, S. S. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.107 · Cited by 70
Nanomedicine-based immunotherapy for central nervous system disorders
Hanif, S., Muhammad, P., Chesworth, R., Rehman, F. U., Qian, R., Zheng, M., & Shi, B. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0429-z · Cited by 75
“In addition, various Aβ-degrading enzymes, such as metalloproteases, insulin-degrading enzyme, and gelatinase A, are also expressed by activated microglia and are responsible for degrading Aβ [179, 180].”
BackgroundGhasemi, R., Zarifkar, A., Rastegar, K., Maghsoudi, N., & Moosavi, M. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.01.036 · Cited by 76
Wang, Y., Hu, H., Liu, X., & Guo, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1138499 · Cited by 76
“The deposition of Aβ plays a role in disrupted insulin signaling, and it can compete with insulin for binding to the insulin receptor thus downregulating PI3K/Akt activation in return (Townsend et al., 2007; Kim and Feldman, 2015).”
BackgroundMoosavi, M., Yadollahikhales, G., Abbasi, L., Zarifkar, A., & Rastegar, K. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.031 · Cited by 70
“Some studies have shown that beta amyloid-induced cell death is accompanied by PI3/Akt or ERK suppression (Townsend et al., 2007; Yin et al., 2005; Zeng et al., 2010).”
BackgroundZheng, Z., Sabirzhanov, B., & Keifer, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.150821 · Cited by 64
Morroni, F., Sita, G., Tarozzi, A., Rimondini, R., & Hrelia, P. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.08.002 · Cited by 68
Lithium as a Treatment for Alzheimer’s Disease: The Systems Pharmacology Perspective
Hampel, H., Lista, S., Mango, D., Nisticò, R., Perry, G., Avila, J., Hernandez, F., Geerts, H., Vergallo, A., (APMI), A. P. M. I., et al. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190197 · Cited by 65
mTOR signaling as a molecular target for the alleviation of Alzheimer's disease pathogenesis
Rapaka, D., Bitra, V. R., Challa, S. R., & Adiukwu, P. C. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105311 · Cited by 70
Adzovic, L., Lynn, A. E., D’Angelo, H. M., Crockett, A. M., Kaercher, R. M., Royer, S. E., Hopp, S. C., & Wenk, G. L. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0321-9 · Cited by 66
Stress-induced anhedonia is associated with an increase in Alzheimer’s disease-related markers
Briones, A., Gagno, S., Martisova, E., Dobarro, M., Aisa, B., Solas, M., Tordera, R., & Ramírez, M. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01602.x · Cited by 64
“Vulnerability to anhedonia is associated with deficits in plasticity markers: effects of venlafaxine Three different markers, already known to be affected by stress, were selected: synaptophysin, widely used to estimate synaptic density (Valtorta et al., 2004); PKB, as part of one of the most critical pathways in regu…”
BackgroundInfluentialThe neuronal insulin receptor in its environment
Gralle, M. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13909 · Cited by 64
“There is evidence that both these pathways are involved in synaptic effects of insulin (Zhao et al. 1999; Dou et al. 2005; Townsend et al. 2007; Kleinridders et al. 2014; see Fig.”
BackgroundEttcheto, M., Petrov, D., Pedrós, I., Alva, N., Carbonell, T., Beas-Zarate, C., Pallas, M., Auladell, C., Folch, J., & Camins, A. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160150 · Cited by 63
“More recently, research in AD has established a clear relationship between obesity, insulin resistance, diabetes, and dementia [18–24].”
BackgroundGhasemi, R., Zarifkar, A., Rastegar, K., Maghsoudi, N., & Moosavi, M. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.034 · Cited by 64
Tran, T. T., Srivareerat, M., & Alkadhi, K. A. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.12.016 · Cited by 60
Fuller, O. K., Whitham, M., Mathivanan, S., & Febbraio, M. A. (2020) · Cells · doi:10.3390/cells9102182 · Cited by 60
Keowkase, R., Aboukhatwa, M. A., & Luo, Y. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.04.008 · Cited by 65
“There is evidence from human and different model organisms indicating a role of insulin receptor/IGF-1 receptor signaling in Aβ metabolism and clearance (Townsend et al., 2007; Zhao et al., 2008; Zhao et al., 2009).”
BackgroundBrambilla, D., Verpillot, R., Taverna, M., Kimpe, L. D., Droumaguet, B. L., Nicolas, J., Canovi, M., Gobbi, M., Mantegazza, F., Salmona, M., et al. (2010) · Analytical Chemistry · doi:10.1021/ac102045x · Cited by 59
Hallmarks of neurodegenerative disease: A systems pharmacology perspective
Bloomingdale, P., Karelina, T., Ramakrishnan, V., Bakshi, S., Véronneau‐Veilleux, F., Moye, M., Sekiguchi, K., Meno‐Tetang, G. M. L., Mohan, A., Maithreye, R., et al. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12852 · Cited by 67
Yang, J., Zeng, F., Li, X., Ran, C., Xu, Y., & Li, Y. (2020) · Chemical Communications · doi:10.1039/c9cc08894f · Cited by 61
Amyloid-Beta Mediates Homeostatic Synaptic Plasticity
Galanis, C., Fellenz, M., Becker, D., Bold, C., Lichtenthaler, S. F., Müller, U. C., Deller, T., & Vlachos, A. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1820-20.2021 · Cited by 51
“Pharmacologic inhibition of CamKII rescues homeostatic synaptic plasticity in APP-deficient preparations Aβ has been linked to inactivation of calcium/calmodulin-dependent protein kinase II [CamKII; (Gu et al., 2009; Townsend et al., 2007; Zhao et al., 2004); but see (Opazo et al., 2018)].”
BackgroundYamamoto, N., Matsubara, T., Sobue, K., Tanida, M., Kasahara, R., Naruse, K., Taniura, H., Sato, T., & Suzuki, K. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07668.x · Cited by 48
“It was reported that the soluble or neurotoxic Ab induced the reduction of PI3K activation (Townsend et al. 2007; Lee et al. 2008).”
BackgroundAssociation of the RAGE G82S polymorphism with Alzheimer’s disease
Daborg, J., von Otter, M., Sjölander, A., Nilsson, S., Minthon, L., Gustafson, D. R., Skoog, I., Blennow, K., & Zetterberg, H. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0437-0 · Cited by 51
“The mechanisms by which Ab inhibit LTP have been elusive and several suggestions have been made (Lauren et al. 2009; Li et al. 2009; Origlia et al. 2009; Townsend et al. 2007).”
BackgroundSaadipour, K., Yang, M., Lim, Y., Georgiou, K., Sun, Y., Keating, D., Liu, J., Wang, Y., Gai, W., Zhong, J., et al. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12383 · Cited by 46
Born to Protect: Leveraging BDNF Against Cognitive Deficit in Alzheimer’s Disease
Caffino, L., Mottarlini, F., & Fumagalli, F. (2020) · CNS Drugs · doi:10.1007/s40263-020-00705-9 · Cited by 56
Purushothaman, A., Babitz, S. K., & Sanderson, R. D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.391417 · Cited by 51
“In some experiments, cells were treatedwith 10 MofAG1024 (SantaCruzBiotechnology) (an inhibitor of insulin receptor tyrosine kinase activity) (27) or 10 M of picropodophyllin (Santa Cruz Biotechnology) (an IGF-1R inhibitor).”
MethodNeuronal receptors as targets for the action of amyloid-beta protein (Aβ) in the brain
Patel, A. N., & Jhamandas, J. H. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002134 · Cited by 43
Memory loss caused by β-amyloid protein is rescued by a β3-adrenoceptor agonist
Gibbs, M. E., Maksel, D., Gibbs, Z., Hou, X., Summers, R. J., & Small, D. H. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.018 · Cited by 53
New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease
Medina, M., & Avila, J. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.843670 · Cited by 50
“Oligomers of the Ab peptide can interact with the insulin [66] or Wnt [67] pathways, leading to an increase in GSK3 activity.”
BackgroundRatia, M., Giménez‐Llort, L., Camps, P., Muñoz‐Torrero, D., Pérez, B., Clos, M. V., & Badía, A. (2012) · Neurodegenerative Diseases · doi:10.1159/000336427 · Cited by 52
The rise and fall of insulin signaling in Alzheimer’s disease
Chami, B., Steel, A. J., de la Monte, S. M., & Sutherland, G. T. (2016) · Metabolic Brain Disease · doi:10.1007/s11011-016-9806-1 · Cited by 55
Oxytocin reverses Aβ-induced impairment of hippocampal synaptic plasticity in mice
Takahashi, J., Yamada, D., Ueta, Y., Iwai, T., Koga, E., Tanabe, M., Oka, J., & Saitoh, A. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.04.046 · Cited by 54
GSK3β Is Involved in the Relief of Mitochondria Pausing in a Tau-Dependent Manner
Llorens-Martín, M., López-Doménech, G., Soriano, E., & Avila, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027686 · Cited by 48
“In AD, Ab peptide binds to Wnt [10], insulin [11] and NMDA [12,13] receptors, all of which promote an increase in”
BackgroundAlzheimer’s disease: amyloid-based pathogenesis and potential therapies
Zhou, Y., Sun, Y., Ma, Q., & Liu, Y. (2018) · Cell Stress · doi:10.15698/cst2018.07.143 · Cited by 53
Young, K. F., Pasternak, S., & Rylett, R. J. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.08.002 · Cited by 56
Alzheimer's disease: Is this a brain specific diabetic condition?
Rani, V., Deshmukh, R. R., Jaswal, P., Kumar, P., & Bariwal, J. B. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.05.041 · Cited by 56
“with or reducing the affinity of insulin binding to its own receptor, (2) inhibition of IR autophosphorylation and subsequent activation of PI3K/Akt [123], (3) causing inhibitory IRS serine phosphorylation by stimulation of c-Jun N-terminal kinase (JNK) [110] and by inhibition of Akt activation by preventing its inter…”
Griffith, C. M., Macklin, L. N., Cai, Y., Sharp, A. A., Yan, X.-X., Reagan, L. P., Strader, A. D., Rose, G. M., & Patrylo, P. R. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180707 · Cited by 43
Amyloid-β Protein Modulates Insulin Signaling in Presynaptic Terminals
Heras-Sandoval, D., Ferrera, P., & Arias, C. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0800-7 · Cited by 48
“Also, low concentrations of soluble Ab [26] and Ab oligomers [27] aberrantly modulate IR function in cultured neurons.”
BackgroundBlazquez-Llorca, L., Garcia-Marin, V., Merino-Serrais, P., Ávila, J., & DeFelipe, J. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110659 · Cited by 44
“We do not know the principal cause for tau phosphorylation at the site recognized by the AT8 antibody, although A oligomers may activate GSK3 [41, 42] that is the kinase that modifies the AT8 site [27].”
BackgroundAdzovic, L., & Domenici, L. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12947 · Cited by 43
“…in patients following intranasal insulin treatment (Reger et al. 2008) and recent results showing that stimulation of insulin signaling protects neurons from Ab toxicity (Townsend et al. 2007; De Felice et al. 2009) suggest that © 2014 International Society for Neurochemistry, J. Neurochem.”
BackgroundInfluentialHebbian and Homeostatic Synaptic Plasticity—Do Alterations of One Reflect Enhancement of the Other?
Galanis, C., & Vlachos, A. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00050 · Cited by 45
“…that Aβ interferes with neural Ca2+ signaling—i.e., it blocks NMDA-Rs and Ca2+/calmodulin-dependent protein kinase II (CamKII; Zhao et al., 2004; Townsend et al., 2007; Gu et al., 2009; but see the work in Opazo et al., 2018, which suggests that Aβ Frontiers in Cellular Neuroscience |…”
BackgroundPires, G., McElligott, S., Drusinsky, S., Halliday, G., Potier, M.-C., Wisniewski, T., & Drummond, E. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0848-6 · Cited by 39
Novel Mediators of Amyloid Precursor Protein Signaling
Swistowski, A., Zhang, Q., Orcholski, M. E., Crippen, D., Vitelli, C., Kurakin, A. V., & Bredesen, D. E. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4351-09.2009 · Cited by 41
“Recent, complementary results argue that signaling events, some of which are mediated by APP itself, also play a crucial role in the development of the AD phenotype (Galvan et al., 2006; Zhao et al., 2006; Townsend et al., 2007; Ma et al., 2008; Nguyen et al., 2008).”
BackgroundInsulin Signaling in Sporadic Alzheimer’s Disease
Liao, F., & Xu, H. (2009) · Science Signaling · doi:10.1126/scisignal.274pe36 · Cited by 47
Glycogen synthase kinase-3β (GSK-3β) and its dysregulation in glioblastoma multiforme
Atkins, R. J., Stylli, S. S., Luwor, R. B., Kaye, A. H., & Hovens, C. M. (2013) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2013.02.003 · Cited by 42
Advances on the Understanding of the Origins of Synaptic Pathology in AD
Lacor, P. (2007) · Current Genomics · doi:10.2174/138920207783769530 · Cited by 38
“Proposed mechanistic pathway for synaptically-bound ADDLs implicated in the induction of aberrations in dendritic spine composition and morphology and how this mechanism is related to synaptic dysfunction and connectivity loss in AD. generated by cleavage of APP can accumulate and adopt oligomeric conformations of the…”
BackgroundInfluentialChan, E. S., Shetty, M. S., Sajikumar, S., Chen, C., Soong, T. W., & Wong, B.-S. (2016) · Scientific Reports · doi:10.1038/srep26119 · Cited by 39
Curtis, D., & Bandyopadhyay, S. (2020) · Annals of Human Genetics · doi:10.1111/ahg.12410 · Cited by 41
“PI3K activation leads to the phosphorylation of Akt1 at two sites: directly at pS473 and indirectly via PDK1 at pT308 (Kanno et al., 2016; Lee et al., 2009; Shi et al., 2014; Townsend et al., 2007).”
BackgroundLi, L., Jadoon, S. S., Liu, S.-Z., Zhang, R., Li, F., Zhang, M.-Y., Ai-Hua, T., You, Q., & Wang, P. (2019) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988719837373 · Cited by 40
Hooshmandi, E., Motamedi, F., Moosavi, M., Katinger, H. W. D., Zakeri, Z., Zaringhalam, J., Maghsoudi, A., Ghasemi, R., & Maghsoudi, N. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.08.001 · Cited by 39
“It has been reported that Ab-induced increasing or decreasing in ERK activity in turn involves the neural cell death or survival (Townsend et al., 2007; Frasca et al., 2008).”
BackgroundRoses, A. D. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.153 · Cited by 39
“The so-called ‘Amyloid Cascade’ involving caspase enzymes may actually be a downstream consequence of mitochondrial toxicity (Townsend et al, 2007; Selkoe and Wolfe, 2007; Walsh and Selkoe, 2007; Dunys et al, 2007; Lee et al, 2007).”
BackgroundArab, L., Sadeghi, R., Walker, D. G., Lue, L.-F., & Sabbagh, M. N. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376334 · Cited by 37
“This has brought up a number of potential mechanisms, including the interaction of insulin degrading enzyme (IDE) in AD and diabetes [42-44]; the involvement of advanced glycation endproduct-modified proteins and the receptor for advanced glycation endproducts (RAGE) [45-47], the interference of A with insulin recepto…”
BackgroundPahnke, J., Fröhlich, C., Krohn, M., Schumacher, T., & Paarmann, K. (2013) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2013.08.007 · Cited by 38
“The IGF-1 pathway is seemingly required for the Aβ’s neuroprotective effect, because Aβ was able to phosphorylate IRS-1 (insulin receptor substrate 1) (Giuffrida et al., 2009) and locally induce insulin production (Townsend et al., 2007) or bind the insulin receptor directly (Xie et al., 2002).”
BackgroundAβ inhibits SREBP-2 activation through Akt inhibition
Mohamed, A., Viveiros, A., Williams, K., & Posse de Chaves, E. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m076703 · Cited by 30
Amyloid-β-Induced Amyloid-β Secretion: A Possible Feed-Forward Mechanism in Alzheimer's Disease
Marsden, I. T., Minamide, L. S., & Bamburg, J. R. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-101899 · Cited by 35
NUB1 modulation of GSK3β reduces tau aggregation
Richet, E., Pooler, A. M., Rodriguez, T., Novoselov, S. S., Schmidtke, G., Groettrup, M., Hanger, D. P., Cheetham, M. E., & van der Spuy, J. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds376 · Cited by 38
Properties of Contextual Memory Formed in the Absence of αCaMKII Autophosphorylation
Irvine, E. E., Danhiez, A., Radwanska, K., Nassim, C., Lucchesi, W., Godaux, E., Ris, L., & Giese, K. P. (2011) · Molecular Brain · doi:10.1186/1756-6606-4-8 · Cited by 34
“This idea may be of relevance for understanding Alzheimer’s disease that has been suggested to be associated with impaired aCaMKII autophosphorylation [29-31].”
BackgroundZhao, H., Zhu, J., Cui, K., Xu, X., O'Brien, M., Wong, K. K., Kesari, S., Xia, W., & Wong, S. T. (2009) · Cancer Cell International · doi:10.1186/1475-2867-9-15 · Cited by 33
Medina, M., & Ávila, J. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.39 · Cited by 38
Liu, X.-H., Geng, Z., Yan, J., Li, T., Chen, Q., Zhang, Q.-Y., & Chen, Z.-Y. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.11.020 · Cited by 32
Noh, M., Chun, K., Kang, B. Y., Kim, H., Park, J., Lee, H., Kim, Y. H., Ku, S., & Kim, S. H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.04.065 · Cited by 32
Yang, Y., Seok, M., Kim, Y. E., Choi, Y., Song, J., Sulistio, Y. A., Kim, S., Chang, M., Oh, S., Nam, M., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01693-6 · Cited by 32
“Furthermore, although expected adverse effects were ruled out in this study, the safety of this gene therapy needs to be carefully addressed before its clinical application.”
Mehan, S., Bhalla, S., Siddiqui, E. M., Sharma, N., Shandilya, A., & Khan, A. (2022) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s247153 · Cited by 29
“Additionally, pretreatment with insulin was effective in reversing this.(39) Synaptotoxic effects are another mechanism by which insulin and Aβ may work together to modify disease.”
Parsons, C., & Rammes, G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1313832 · Cited by 31
“Some researchers believe that dimers and trimers are the ‘synaptotoxic species’ [108,109] while others favor dodecameric species [11,93].”
BackgroundChan, E. S., Chen, C., Cole, G. M., & Wong, B.-S. (2015) · Scientific Reports · doi:10.1038/srep13842 · Cited by 29
Ghasemi, R., Moosavi, M., Zarifkar, A., Rastegar, K., & Maghsoudi, N. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0622-6 · Cited by 32
Li, Y., Li, L., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0018 · Cited by 31
“Furthermore, brain insulin signaling is particularly important for learning and memory (Townsend et al., 2007; Freiherr et al., 2013) and provides a physiological defense mechanism against oligomer-induced synapse loss (De Felice et al., 2009) and furthermore protects neurons from the…”
BackgroundIzumi, H., Shinoda, Y., Saito, T., Saido, T. C., Sato, K., Yabuki, Y., Matsumoto, Y., Kanemitsu, Y., Tomioka, Y., Abolhassani, N., et al. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.02.031 · Cited by 29
Kim, J. E., Park, J. J., Lee, M. R., Choi, J. Y., Song, B., Park, J. W., Kang, M. J., Son, H. J., Hong, J. T., & Hwang, D. Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215205 · Cited by 30
Intraneuronally injected amyloid beta inhibits long-term potentiation in rat hippocampal slices
Nomura, I., Takechi, H., & Kato, N. (2012) · Journal of Neurophysiology · doi:10.1152/jn.00589.2011 · Cited by 28
Zhang, W., Jiao, B., Zhou, M., Zhou, T., & Shen, L. H. (2016) · Stem Cells International · doi:10.1155/2016/7828049 · Cited by 30
Logan, S. M., Sarkar, S. N., Zhang, Z., & Simpkins, J. W. (2011) · Brain Research · doi:10.1016/j.brainres.2011.01.038 · Cited by 29
“Acute application of soluble Aβ oligomers impaired CaMKII, ERK, and Akt/ protein kinase B (PKB) activation in mature hippocampal culture (Townsend et al., 2007).”
BackgroundInfluentialGuillot, F., Kemppainen, S., Lavasseur, G., Miettinen, P. O., Laroche, S., Tanila, H., & Davis, S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150926 · Cited by 26
“Evidence also suggests that A directly interferes with signal transduction through the insulin/IGF [22] and trkB [23] receptors.”
Waigi, E. W., Webb, R. C., Moss, M. A., Uline, M. J., McCarthy, C. G., & Wenceslau, C. F. (2023) · GeroScience · doi:10.1007/s11357-023-00748-y · Cited by 28
Simón, D., Herva, M. E., Benítez, M. J., Garrido, J. J., Rojo, A. I., Cuadrado, A., Torres, J. M., & Wandosell, F. G. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12066 · Cited by 26
Erythrocytes as Potential Link between Diabetes and Alzheimer’s Disease
Carelli‐Alinovi, C., & Misiti, F. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00276 · Cited by 26
“Aβ is able to bind IR in a competitive way, inhibiting its auto-phosphorylation and downstream kinases necessary for neuronal function in hippocampal region (Townsend et al., 2007).”
BackgroundMcNay, E. C., & Recknagel, A. K. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.11.001 · Cited by 28
Metadata
- Authors
- Townsend, M., Mehta, T., & Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Selkoe, Dennis J.
- ORCID
- Selkoe, Dennis J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2007-11
- Volume
- 282
- Issue
- 46
- Pages
- 33305-33312
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2058581619
- Cited by
- 318
- References
- 55
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 4 · 2023: 8 · 2022: 15 · 2021: 6 · 2020: 13 · 2019: 9 · 2018: 12 · 2017: 14 · 2016: 26 · 2015: 19 · 2014: 22 · 2013: 26 · 2012: 40
- FWCI
- 13.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 4724 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (AG027443, R01AG027443)
- National Institute of Neurological Disorders and Stroke (T32 NS07484-04, T32NS007484)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, insulin receptor, signal transduction, long-term potentiation, ERK MAPK, CaMKII, Akt/protein kinase B, phosphatidylinositol 3-kinase, protein kinase A, protein kinase C, kinase autophosphorylation, hippocampal neurons, Alzheimer's disease, amyloid hypothesis, synaptic plasticity
- MeSH terms
- Animals, Cricetulus, Electrophysiology, Enzyme Activation, Cricetinae, Hippocampus, Humans, Insulin, Models, Biological, Phosphorylation, Receptor, Insulin, Signal Transduction, Amyloid beta-Peptides, CHO Cells, Long-Term Potentiation, Phosphatidylinositol 3-Kinases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.